Literature DB >> 16386623

Decreased levels of serum immunoglobulins as a risk factor for infection after heart transplantation.

E Sarmiento1, J Rodríguez-Molina, P Muñoz, J Fernández-Yánez, J Palomo, M Fogueda, E Fernández-Cruz, E Bouza, J Carbone.   

Abstract

OBJECTIVE: We aimed to assess humoral immunity markers that provide prognostic value for the development of infections in heart transplant recipients. PATIENTS AND METHODS: Forty-one heart transplant recipients underwent humoral immunity studies, including Immunoglobulin (IgG, IgA, IgM) and IgG subclasses determined by nephelometry on serum samples obtained before transplantation and 1 month after transplantation. Potential clinical risk factors were evaluated: waiting time for transplantation, pretransplant cytomegalovirus (CMV) serologic status of donor and recipient; recipient age; gender; cardiac disease severity before transplantation; type of immunosuppression; and occurrence of rejection. OUTCOME MEASURES: We measured infections requiring intravenous (IV) drug therapy during the first year. The association between variables and outcome was assessed using Cox proportional hazards modelling. Immunoglobulin levels were split into two groups using the median value observed as the cut-off.
RESULTS: Of 41 patients studied, 19 (46%) had at least one episode of infection, 16 of which were CMV infections treated with IV gancyclovir, 1 CMV disease + aspergillosis and 2 bacterial pneumonia. Pretransplant IgG (<1055 mg/dL; RR 5.32; 95% confidence interval [CI] 1.73 to 16.29; P = .0034); pretransplant IgG1 (<695 mg/dL; RR 4.80; CI 1.57 to 14.68; P = .006), and posttransplant IgG levels (<589 mg/dL; RR 3.38; CI 1.21 to 9.44, P = .019) were associated with an increased risk of developing infections. Both waiting time for transplantation (RR 0.95; CI 0.91 to 0.98, P = .007) and pretransplant cardiac disease severity (RR 1.94; CI 1.17 to 3.21, P = .009) were significant risk factors for infection. After adjustment for clinical predictive variables, decreased values of posttransplant IgG remained significant predictors.
CONCLUSIONS: The existence of decreased levels of IgG in the setting of heart transplantation was associated with an higher risk for infection. Monitoring of immunoglobulin levels, a rapid and well-standardized nephelometric determination, in heart transplantation, may identify a subset of patients at risk for development of infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16386623     DOI: 10.1016/j.transproceed.2005.09.153

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

1.  Clostridium difficile Infection (CDI) in Solid Organ and Hematopoietic Stem Cell Transplant Recipients.

Authors:  Carolyn D Alonso; Mini Kamboj
Journal:  Curr Infect Dis Rep       Date:  2014-08       Impact factor: 3.725

2.  Acquired hypogammaglobulinemia and pathogen-specific antibody depletion after solid organ transplantation in human immunodeficiency virus infection: A brief report.

Authors:  Margaret Newman; Kevin Gregg; Randee Estes; Kenneth Pursell; David Pitrak
Journal:  Transpl Infect Dis       Date:  2019-10-14       Impact factor: 2.228

Review 3.  CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients.

Authors:  Uwe Schulz; Paolo Solidoro; Veronika Müller; Attila Szabo; Jens Gottlieb; Heinrike Wilkens; Frank Enseleit
Journal:  Transplantation       Date:  2016-03       Impact factor: 4.939

Review 4.  The Immunology of Posttransplant CMV Infection: Potential Effect of CMV Immunoglobulins on Distinct Components of the Immune Response to CMV.

Authors:  Javier Carbone
Journal:  Transplantation       Date:  2016-03       Impact factor: 4.939

Review 5.  The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management.

Authors:  Smita Y Patel; Javier Carbone; Stephen Jolles
Journal:  Front Immunol       Date:  2019-02-08       Impact factor: 7.561

6.  IgA, albumin, and eosinopenia as early indicators of cytomegalovirus infection in patients with acute ulcerative colitis.

Authors:  Hong Yang; Kaichun Wu; Hongjie Zhang; Qin Owyang; Yinglei Miao; Fang Gu; Naizhong Hu; Kaifang Zou; Jianqiu Sheng; Jin Li; Ping Zheng; Yulan Liu; Junxia Li; Xiaodi Wang; Yongdong Wu; Yaozong Yuan; Chunxiao Chen; Yanhua Pang; Meihua Cui; Jiaming Qian
Journal:  BMC Gastroenterol       Date:  2020-09-05       Impact factor: 3.067

Review 7.  Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations.

Authors:  Hans-Hartmut Peter; Hans D Ochs; Charlotte Cunningham-Rundles; Donald C Vinh; Peter Kiessling; Bernhard Greve; Stephen Jolles
Journal:  J Allergy Clin Immunol       Date:  2020-09       Impact factor: 10.793

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.